Where is MOTS-c usually injected?

The available human trial records use subcutaneous tissue, the fatty layer beneath the skin. The abdomen and thigh are the areas named in the completed CB4211 analogue trial, while the ongoing native-MOTS-c trial lists the route but no body site. The outer upper arm is common for other subcutaneous medicines. The pharmacy label and prescriber determine the site for an individual preparation.

Is MOTS-c injected subcutaneously or intramuscularly?

The available human trial records use subcutaneous administration. No published human study compares subcutaneous with intramuscular MOTS-c, and the animal studies often cited online used injection into the abdominal cavity, not muscle. These routes are not interchangeable because they place material into tissues with different blood flow and absorption. The prescribed route comes from the provider and pharmacy label.

Why should MOTS-c injection sites be rotated?

Rotation spreads repeated tissue stress across approved spots instead of returning to one small patch. Direct MOTS-c rotation studies do not exist, but broader subcutaneous-injection evidence links poor rotation with fatty tissue thickening and lumps. Rotation does not change the dose or make a new body area suitable; the exact pattern should match the site range on the pharmacy's directions.

What should a MOTS-c injection-site reaction look like?

A mild local reaction may involve brief redness, tenderness, itching, or swelling where the needle entered, although MOTS-c-specific rates have not been established. Spreading redness, increasing warmth, drainage, a persistent hard lump, hives, facial swelling, or breathing trouble is a different pattern. A worsening or persistent reaction needs prompt clinical review, while breathing trouble or facial swelling requires emergency care.

MOTS-c has no FDA-approved product, and the compounded formulation offered here is not FDA-approved. In 2026, FDA staff reviewed its free-base and acetate forms for possible inclusion on the section 503A bulk-substances list and raised unresolved quality and immune-response questions. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.

Where to Inject MOTS-c: What the Evidence Says

Where to inject MOTS-c has a short answer: the available human trial records use a subcutaneous site, meaning the fatty layer just beneath the skin. The abdomen and thigh are the clearest sites in those records. The outer upper arm is another common subcutaneous area, but it isn't named in a completed MOTS-c study. The prescription label and the reviewing provider decide which area applies to the exact preparation.

That distinction matters because no completed human trial has published an injection-site comparison for native MOTS-c. An online diagram may look precise while resting on very thin evidence.

Where to inject MOTS-c: what the studies show

Two trial records point to the subcutaneous route. Neither supplies a general-purpose injection guide.

The completed Phase 1a/1b study enrolled 88 people and tested CB4211, an analogue—a modified relative—of MOTS-c. Its ClinicalTrials.gov record says study staff gave bolus injections into the abdomen and, when needed, the upper or lower thigh. No results are posted there. More importantly, CB4211 is not native MOTS-c, so its route is useful context rather than proof that every MOTS-c preparation behaves the same way.

A newer Phase 2a study of native MOTS-c began in February 2026 and plans to enroll 120 adults with prediabetes and overweight or obesity. The MOTS-MET record also lists subcutaneous injection for 12 weeks, but it doesn't identify a body site or disclose the fixed dose. It has no results yet.

The biology is still young. The original 2015 paper identified MOTS-c as a 16-amino-acid mitochondrial peptide, but its treatment experiments were in mice, not people (Lee et al., Cell Metabolism 2015). Those mouse injections went into the abdominal cavity, a laboratory route that doesn't establish a human injection site.

The usual subcutaneous areas, in plain language

Subcutaneous tissue is the soft layer between skin and muscle. It has less blood flow than muscle, so route and placement can change how a medicine is absorbed. A literature review found that the depth of fatty tissue and the matching needle length matter to whether a shot reaches its intended layer (Annersten and Willman, Worldviews on Evidence-Based Nursing 2005).

Area	What the evidence says	What it does not say
Abdomen	Named first in the CB4211 trial record	That every spot on the abdomen is suitable
Front or outer thigh	Named as an alternate area in the CB4211 record	That thigh placement is better for native MOTS-c
Outer upper arm	A common subcutaneous area for other injected medicines	That a MOTS-c trial compared it with abdomen or thigh

A prescriber may rule out tender, bruised, scarred, hardened, or irritated skin. The usable area also depends on body build, needle, volume, and formulation. Those are reasons the pharmacy's directions outrank a one-size-fits-all body map.

Subcutaneous and intramuscular are not interchangeable

Subcutaneous, often shortened to sub-Q, means beneath the skin. Intramuscular, or IM, means deeper into muscle. They are different tissue compartments with different blood flow and absorption.

No published human study has compared sub-Q with IM MOTS-c. The two human trial records above use subcutaneous administration. The founding mouse paper used intraperitoneal administration—inside the abdominal cavity—not IM. So a claim that intramuscular MOTS-c is faster, stronger, or preferred isn't supported by those studies.

This is also why evidence from SS-31 cannot settle the question. SS-31, also called elamipretide, is a different mitochondria-focused peptide with its own formulation and clinical program. A route used for one peptide doesn't validate a route for another.

Rotation protects the skin, not the dose

Rotation means spacing repeated injections across approved spots rather than returning to one small patch. It is about reducing repeated tissue stress. It does not change the prescribed amount or create a new approved region.

As of September 9, 2026, the day this article was written, a July 3 consensus paper on insulin injections identified poor site rotation as the strongest modifiable risk factor for lipohypertrophy, which is a thickened fatty lump under the skin. That paper concerns insulin, not MOTS-c, so it supports the reason for rotation without establishing a MOTS-c schedule.

A useful rotation plan is specific enough to prevent accidental reuse and simple enough to follow. The provider or dispensing pharmacy can show how the approved region is divided for the prescribed product.

What an injection-site reaction can look like

A local reaction is a change where the needle entered. Across 158 trials of other injected biologic medicines, redness, pain, and itching were among the most commonly reported reaction types (Kim and colleagues, Journal of Cutaneous Medicine and Surgery 2023). Those percentages cannot be transferred to MOTS-c, but the names help make sense of what “site reaction” means.

Brief tenderness or a small red area is different from spreading redness, increasing warmth, drainage, a persistent hard lump, hives, or trouble breathing. The prescriber should hear promptly about a reaction that is worsening or not settling; breathing trouble or facial swelling requires emergency care.

The MOTS-c side-effects guide covers the wider safety uncertainty. For site choice, the main point is simpler: a sore or altered patch is not a neutral place to keep using while someone guesses what caused it.

The 2026 FDA review does not create an injection map

As of September 9, 2026, the day this article was written, the FDA's July 23 advisory-committee meeting had considered MOTS-c free base and acetate for the section 503A bulk-substances list. FDA staff's May 11 briefing proposed not adding either form after finding no published human administration data and unresolved questions about impurities, peptide clumping, and immune reactions. An advisory committee gives non-binding advice; the meeting was not a drug approval or an injection-site study.

MOTS-c has no FDA-approved product, and the compounded formulation offered here is not FDA-approved. Regulatory status is one part of a medical decision. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor.

The pharmacy label is the map that matters

The MOTS-c dosage guide explains why there is no standard human amount, while when to take MOTS-c covers the separate timing question. Site, amount, concentration, needle, frequency, and timing need to describe one prescription—not a protocol assembled from unrelated webpages.

At Promise, a licensed provider reviews every request and prescribes only when MOTS-c is appropriate; not everyone qualifies. If prescribed, the pharmacy label and clinical team provide the directions for that preparation and resolve any mismatch between the label, supplies, and prior instructions.